- Resource
- Source: Campus Sanofi
- 19 Nov 2025
5 min
Guidelines for RSV prevention with Nirsevimab
Respiratory Syncytial Virus (RSV) is a major cause of lower respiratory tract infections in infants and young children. Nirsevimab is a long-acting monoclonal antibody that provides passive immunization against RSV, offering protection throughout the RSV season with a single dose
MAT-BH-2500639/V1/December2025